安罗替尼对非小细胞肺癌患者肺功能的影响及安全性分析  

Effects of Anlotinib on Lung Function and Safety in Patients with Non-Small Cell Lung Cancer

作　　者：段春霞[1] 张志强[2] 白庆阳[1] DUAN Chun-xia;ZHANG Zhi-qiang;BAI Qing-yang(The First Affiliated Hospital of Baotou Medical College,Inner Mongolia University o f Science and Technology,Baotou 014010,China;The Third Hospital of Inner Mongolia BaoGang Group,Baotou 014010,China)

机构地区：[1]内蒙古科技大学包头医学院第一附属医院,包头014010 [2]内蒙古包钢集团第三职工医院,包头014010

出　　处：《中国合理用药探索》2022年第9期43-47,共5页Chinese Journal of Rational Drug Use

摘　　要：目的:探讨安罗替尼治疗非小细胞肺癌(NSCLC)患者的临床疗效及其对肺功能、免疫功能的影响,并评估用药安全性。方法:选取2020年4月~2021年12月期间本院收治的90例NSCLC患者作为研究对象,采用随机数字表法分为对照组和观察组,每组45例。对照组给予化疗治疗,观察组在化疗基础上加用安罗替尼。比较两组的临床疗效、第1秒用力呼气容积(FEV_(1))、用力肺活量(FVC)、1秒率(FEV_(1)/FVC)等肺功能指标水平,以及自然杀伤细胞(NK cell)、CD4^(+)、CD3^(+)等免疫功能指标水平、细胞生长因子指标水平和不良反应发生情况。结果:观察组治疗总有效率(84.44%)高于对照组(60.00%,P<0.05);治疗前,两组肺功能指标水平比较无统计学差异(P>0.05),治疗后,观察组肺功能指标水平高于对照组(P<0.05);治疗前,两组免疫功能指标水平比较无统计学差异(P>0.05),治疗后,观察组免疫功能指标水平高于对照组(P<0.05);治疗前,两组细胞生长因子指标水平比较无统计学差异(P>0.05),治疗后,观察组细胞生长因子指标水平低于对照组(P<0.05);观察组不良反应发生率(6.67%)低于对照组(8.89%,P>0.05)。结论:在化疗基础上给予安罗替尼治疗,能够更好地改善NSCLC患者的机体免疫功能、肺功能,且安全性较高。Objective:To investigate the effect of anlotinib on clinical efficacy,lung function and immune function in patients with non-small cell lung cancer(NSCLC),and to evaluate its safety.Methods:A total of 90 patients with non-small cell lung cancer admitted to our hospital from April 2020 to December 2021 were selected as the research objects,and divided into control group and observation group by random number table method,45 cases in each group.The control group received chemotherapy,and the observation group was given anlotinib on the basis of chemotherapy.The therapeutic efficacy,forced expiratory volume in 1 second,forced vital capacity,FEV_(1)/FVC and other pulmonary function indicators,the levels of NK cell,CD4^(+),CD3^(+)and other immune function indicators,and adverse reactions of the two groups were compared.Results:The therapeutic effect of the observation group(84.44%)was higher than that of the control group(60.00%,P<0.05).Before treatment,there was no significant difference in lung function between the two groups(P>0.05).After treatment,the lung function index of the observation group was higher than that of the control group(P<0.05).Before treatment,there was no significant difference in immune function between the two groups(P>0.05).After treatment,the immune function index of the observation group was higher than that of the control group(P<0.05).Before treatment,there was no significant difference in cell growth factor indexes between the two groups(P>0.05).After treatment,the cell growth factor index in the observation group was lower than that in the control group(P<0.05).The incidence of adverse reactions in the observation group(6.67%)was lower than that in the control group(8.89%,P>0.05).Conclusion:Anlotinib on the basis of chemotherapy can better improve the immune function and lung function of patients with non-small cell lung cancer,and has high safety.

关 键 词：非小细胞肺癌 安罗替尼 肺功能 化疗 免疫功能 

分 类 号：R734.2[医药卫生—肿瘤]